Sentence examples for long-term exacerbation from inspiring English sources

Mean reliever use over 1 week was predictive of long-term exacerbation risk.

Budesonide/formoterol was associated with lower short- and long-term exacerbation risk than formoterol in all reliever-use groups.

We hypothesized that short-acting β2-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients.

The long-term exacerbation risk was evaluated as the relationship between mean reliever use during stable treatment in the week before the 2-month study visit and probability of an exacerbation occurring in months 3 12 of the study.

SABA reliever use is a predictor of short- and long-term exacerbation risk in moderate-to-very-severe COPD patients with a history of exacerbations receiving budesonide/formoterol or formoterol.

In addition, data were available for 674 patients in the long-term exacerbation risk analysis: 234, 155, and 92 patients reached the mean number of inhalations/day for inclusion in the low (2 5 inhalations/day), medium (6 9 inhalations/day), and high (>10 inhalations/day) reliever use subgroups, respectively.> -wrap-foot> Data shown as mean (±SD), unless otherwise stated.

Future research should focus about randomised controlled trials to more thoroughly describe effects of WBV and a potential placebo affecting people with COPD and describe the economic feasibility and long-term exacerbations of standalone community-based WBV interventions.

In conclusion, the present study showed that long-term mortality after exacerbation of obstructive lung disease is strongly affected by the history of diabetes.

For both treatments, long-term 10-month exacerbation rates were greater whenever mean reliever use exceeded thresholds, in the range from 0 12 inhalations/day in the week preceding the 2-month visit (Fig.  2).

Mean daily reliever use in the week preceding the 2-month visit was investigated as a predictor of the long-term (10-month) exacerbation risk, using intervals of 2 5, 6 9, and ≥10 inhalations/day.

This was true for patients taking BUD/FORM and FORM alone; however, patients treated with BUD/FORM had a lower short- and long-term risk of exacerbation compared with FORM monotherapy.